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Background: Most of the validation work regarding Paclitaxel Coated Balloon (PCB) technologies has been performed in the coronary territory of 
juvenile domestic swine. Although invaluable for the evaluation of safety, this model is not properly suited for the evaluation of efficacy of peripheral 
PCB technologies. In this study, we aimed to validate a novel ilio-femoral in-stent restenosis (ISR) model for the efficacy evaluation of PCB using the 
familial hypercholesterolemic swine (FHS).
Methods: A total of 24 Ilio-femoral segments in 12 FHS underwent balloon injury and self-expanding stent placement at a baseline procedure. 
After 21 days, the resulting ISR lesions were treated with either 1μg/mm2-dose (n=8), 3μg/mm2-dose (n=8) PCB (Cotavance® PCB angioplasty 
catheter,Bayer Pharma AG/MEDRAD Inc., Indianola, PA) or an identical uncoated control balloon (n=8). Angiography (QVA), Intravascular Ultrasound 
(IVUS) and histomorphometric analysis were used to assess and compare the final neointimal response at 28 days after treatment (49 days).
Results: At termination, the percent diameter stenosis by QVA in the control group was higher (31.2%±13.7%) compared to the 1μg/mm2 
(19.3%±14.0%, 38% reduction) and 3μg/mm2 (8.6%±10.7%, 72% reduction) PCB groups. IVUS analysis confirmed these findings and showed a 
reduction of 36% (1μg/ mm2-dose, p=0.04) and 55% (3μg/ mm2-dose, p<0.01) in neointimal volume of stenosis compared to the uncoated control 
group. In the histological analysis, the control group showed the highest degree of percentage area of stenosis (PAS= 65%±14.3%). The reduction in 
PAS was 13.2 % (p=0.5) and 26 %( p=0.04) in the 1μg/mm2 and 3μg/ mm2 dose respectively. 
Conclusions: The FHS model of Iliofemoral-ISR demonstrated a dose dependent effect on the inhibition of neointimal proliferation of a clinically 
validated PCB technology. This model represents a positive step forward towards the evaluation of efficacy of PCB technologies in this territory.
